Cargando…

Integration of phospholipid-complex nanocarrier assembly with endogenous N-oleoylethanolamine for efficient stroke therapy

BACKGROUND: Leading to more and more deaths and disabilities, stroke has become a serious threat to human health. What’s more, few effective drugs are available in clinic till now. RESULTS: In this research, we prepared a novel neuroprotective nanoformation (OEA–SPC NPs) via the combination of the n...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xiangrui, Xu, Lanxi, Zhou, Juan, Ge, Yunlong, Wu, Shichao, Huang, Junxiong, Li, Ying, Zhu, Maoshu, Jin, Xin, Yang, Lichao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339692/
https://www.ncbi.nlm.nih.gov/pubmed/30660200
http://dx.doi.org/10.1186/s12951-019-0442-x
_version_ 1783388671226937344
author Yang, Xiangrui
Xu, Lanxi
Zhou, Juan
Ge, Yunlong
Wu, Shichao
Huang, Junxiong
Li, Ying
Zhu, Maoshu
Jin, Xin
Yang, Lichao
author_facet Yang, Xiangrui
Xu, Lanxi
Zhou, Juan
Ge, Yunlong
Wu, Shichao
Huang, Junxiong
Li, Ying
Zhu, Maoshu
Jin, Xin
Yang, Lichao
author_sort Yang, Xiangrui
collection PubMed
description BACKGROUND: Leading to more and more deaths and disabilities, stroke has become a serious threat to human health. What’s more, few effective drugs are available in clinic till now. RESULTS: In this research, we prepared a novel neuroprotective nanoformation (OEA–SPC NPs) via the combination of the nanoparticle drug delivery system with the endogenous N-oleoylethanolamine (OEA). By forming hydrogen bond between OEA and the carrier—soybean phosphatidylcholine (SPC), the form of OEA was turned into amorphus state when loading to the nanoparticles, which greatly improved its bioavailability. Then the following systematic experiments revealed the efficient neuroprotective effect of OEA–SPC NPs in vivo. Compared with the MCAO group, the cerebral infarct volume was reduced by 81.1%, and the edema degree by 78.4% via the oral administration of OEA–SPC NPs. And the neurological deficit scores illustrated that the MCAO rats treated with OEA–SPC NPs exhibited significantly less neurological dysfunction. The Morris water maze test indicated that the spatial learning and memory of cerebral ischemia model rats were almost recovered to the normal level. Besides, the OEA–SPC NPs could inhibit the inflammation of reperfusion to a very slight level. CONCLUSIONS: These results suggest that the OEA–SPC NPs have a great chance to be a potential anti-stroke formation for clinic application and actually bring hope to thousands of stroke patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12951-019-0442-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6339692
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63396922019-01-24 Integration of phospholipid-complex nanocarrier assembly with endogenous N-oleoylethanolamine for efficient stroke therapy Yang, Xiangrui Xu, Lanxi Zhou, Juan Ge, Yunlong Wu, Shichao Huang, Junxiong Li, Ying Zhu, Maoshu Jin, Xin Yang, Lichao J Nanobiotechnology Research BACKGROUND: Leading to more and more deaths and disabilities, stroke has become a serious threat to human health. What’s more, few effective drugs are available in clinic till now. RESULTS: In this research, we prepared a novel neuroprotective nanoformation (OEA–SPC NPs) via the combination of the nanoparticle drug delivery system with the endogenous N-oleoylethanolamine (OEA). By forming hydrogen bond between OEA and the carrier—soybean phosphatidylcholine (SPC), the form of OEA was turned into amorphus state when loading to the nanoparticles, which greatly improved its bioavailability. Then the following systematic experiments revealed the efficient neuroprotective effect of OEA–SPC NPs in vivo. Compared with the MCAO group, the cerebral infarct volume was reduced by 81.1%, and the edema degree by 78.4% via the oral administration of OEA–SPC NPs. And the neurological deficit scores illustrated that the MCAO rats treated with OEA–SPC NPs exhibited significantly less neurological dysfunction. The Morris water maze test indicated that the spatial learning and memory of cerebral ischemia model rats were almost recovered to the normal level. Besides, the OEA–SPC NPs could inhibit the inflammation of reperfusion to a very slight level. CONCLUSIONS: These results suggest that the OEA–SPC NPs have a great chance to be a potential anti-stroke formation for clinic application and actually bring hope to thousands of stroke patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12951-019-0442-x) contains supplementary material, which is available to authorized users. BioMed Central 2019-01-19 /pmc/articles/PMC6339692/ /pubmed/30660200 http://dx.doi.org/10.1186/s12951-019-0442-x Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Yang, Xiangrui
Xu, Lanxi
Zhou, Juan
Ge, Yunlong
Wu, Shichao
Huang, Junxiong
Li, Ying
Zhu, Maoshu
Jin, Xin
Yang, Lichao
Integration of phospholipid-complex nanocarrier assembly with endogenous N-oleoylethanolamine for efficient stroke therapy
title Integration of phospholipid-complex nanocarrier assembly with endogenous N-oleoylethanolamine for efficient stroke therapy
title_full Integration of phospholipid-complex nanocarrier assembly with endogenous N-oleoylethanolamine for efficient stroke therapy
title_fullStr Integration of phospholipid-complex nanocarrier assembly with endogenous N-oleoylethanolamine for efficient stroke therapy
title_full_unstemmed Integration of phospholipid-complex nanocarrier assembly with endogenous N-oleoylethanolamine for efficient stroke therapy
title_short Integration of phospholipid-complex nanocarrier assembly with endogenous N-oleoylethanolamine for efficient stroke therapy
title_sort integration of phospholipid-complex nanocarrier assembly with endogenous n-oleoylethanolamine for efficient stroke therapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339692/
https://www.ncbi.nlm.nih.gov/pubmed/30660200
http://dx.doi.org/10.1186/s12951-019-0442-x
work_keys_str_mv AT yangxiangrui integrationofphospholipidcomplexnanocarrierassemblywithendogenousnoleoylethanolamineforefficientstroketherapy
AT xulanxi integrationofphospholipidcomplexnanocarrierassemblywithendogenousnoleoylethanolamineforefficientstroketherapy
AT zhoujuan integrationofphospholipidcomplexnanocarrierassemblywithendogenousnoleoylethanolamineforefficientstroketherapy
AT geyunlong integrationofphospholipidcomplexnanocarrierassemblywithendogenousnoleoylethanolamineforefficientstroketherapy
AT wushichao integrationofphospholipidcomplexnanocarrierassemblywithendogenousnoleoylethanolamineforefficientstroketherapy
AT huangjunxiong integrationofphospholipidcomplexnanocarrierassemblywithendogenousnoleoylethanolamineforefficientstroketherapy
AT liying integrationofphospholipidcomplexnanocarrierassemblywithendogenousnoleoylethanolamineforefficientstroketherapy
AT zhumaoshu integrationofphospholipidcomplexnanocarrierassemblywithendogenousnoleoylethanolamineforefficientstroketherapy
AT jinxin integrationofphospholipidcomplexnanocarrierassemblywithendogenousnoleoylethanolamineforefficientstroketherapy
AT yanglichao integrationofphospholipidcomplexnanocarrierassemblywithendogenousnoleoylethanolamineforefficientstroketherapy